Navigation Links
John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners

ST. LOUIS, May 3, 2011 /PRNewswire/ -- RiverVest Venture Partners®, a venture capital firm investing in emerging medical technology and biopharmaceutical companies, today announced that John McKearn, Ph.D., has been promoted to Managing Director.  

Dr. McKearn joined RiverVest as Venture Partner in 2008, bringing extensive scientific and operational expertise in pharmaceutical research and development as former president and CEO of Kalypsys, Inc.; head of discovery research for Pharmacia and Searle; and senior scientist with E.I. DuPont de Nemours and Company.

"John has been a valuable addition to the RiverVest team and we are pleased to promote him," said Jay Schmelter, RiverVest Managing Director. "His deep knowledge of pharmaceutical research and development is instrumental in enhancing the drug development programs of our portfolio companies and securing important venture capital financing opportunities."

Most recently, Dr. McKearn helped originate and structure a $38.5 million Series B financing for Otonomy, Inc., a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. The deal, which closed in August 2010, was co-led by Novo Ventures and RiverVest Venture Partners, and joined by TPG Biotech, Domain Associates and Avalon.

"This is an exciting time for RiverVest," said Dr. McKearn. "As a team, we are uniquely positioned in a marketplace that has been defined in recent years as harsh, frenetic and out of balance. We continue to leverage our deep operating experience to attract and shape promising biopharmaceutical opportunities and build value for our portfolio companies."  

Dr. McKearn holds a Ph.D. in immunology from the University of Chicago and a B.S. in biology from Northern Illinois University. He currently serves as a member of the board of directors for Otonomy, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc.  Dr. McKearn holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease.

About RiverVest Venture Partners

RiverVest is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit. For more information, please visit

SOURCE RiverVest Venture Partners
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
2. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
3. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
4. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
5. American Humane Association Announces Joy Mench, Ph.D., Joins the Scientific Advisory Committee of the American Humane Certified® Farm Animal Program
6. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
7. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
8. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. 5th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Peter K. Vogt, Ph.D., The Scripps Research Institute
11. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):